Stephens Investment Management Group LLC Reduces Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Stephens Investment Management Group LLC lessened its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 0.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,738,482 shares of the specialty pharmaceutical company's stock after selling 13,586 shares during the quarter. Stephens Investment Management Group LLC owned about 3.11% of Supernus Pharmaceuticals worth $56,935,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of SUPN. Woodline Partners LP raised its stake in shares of Supernus Pharmaceuticals by 124.8% during the 4th quarter. Woodline Partners LP now owns 423,828 shares of the specialty pharmaceutical company's stock worth $15,326,000 after acquiring an additional 235,257 shares in the last quarter. BNP Paribas Financial Markets grew its position in Supernus Pharmaceuticals by 248.0% during the 4th quarter. BNP Paribas Financial Markets now owns 292,629 shares of the specialty pharmaceutical company's stock worth $10,581,000 after purchasing an additional 208,552 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Supernus Pharmaceuticals during the 4th quarter worth approximately $6,847,000. D. E. Shaw & Co. Inc. grew its position in Supernus Pharmaceuticals by 33.5% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 545,658 shares of the specialty pharmaceutical company's stock worth $19,731,000 after purchasing an additional 136,870 shares during the last quarter. Finally, Cubist Systematic Strategies LLC grew its position in Supernus Pharmaceuticals by 944.2% during the 4th quarter. Cubist Systematic Strategies LLC now owns 139,522 shares of the specialty pharmaceutical company's stock worth $5,045,000 after purchasing an additional 126,161 shares during the last quarter.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday.

Supernus Pharmaceuticals Price Performance

NASDAQ:SUPN traded down $0.02 during trading hours on Friday, hitting $33.12. 461,128 shares of the company were exchanged, compared to its average volume of 487,598. The stock has a market capitalization of $1.85 billion, a price-to-earnings ratio of 29.84 and a beta of 0.70. Supernus Pharmaceuticals, Inc. has a 52-week low of $27.05 and a 52-week high of $40.28. The company's 50 day moving average price is $32.26 and its 200-day moving average price is $33.75.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.